article thumbnail

New Treatment Options Available for Patients with Tricuspid Valve Disease

DAIC

In tricuspid valve regurgitation, a complex condition that Cedars-Sinai experts regularly treat, the valve between two heart chambers on the right side doesn't open or close properly. Makkar explained the advances for patients with tricuspid valve disease in a conversationwith the Cedars-Sinai Newsroom. Image by Getty. Image by Getty.

article thumbnail

FDA Advisory Committee Votes in Favor of Abbott’s First-of-its-kind Triclip System to Treat People with a Leaky Tricuspid Heart Valve

DAIC

Food and Drug Administration ( FDA ) confirmed 13 to 1, with 0 abstention that the benefits of Abbott's TriClip™ transcatheter edge-to-edge repair (TEER) system outweighed the risks for the treatment of people with tricuspid regurgitation (TR). On the final question of the benefit of TriClip versus the risk, the vote was 13 to 1 in favor.

Tricuspid 102
article thumbnail

Atrial dilatation in Atrial fibrillation : A query with multiple twists!

Dr. S. Venkatesan MD

When atrial fibrillation (AF) begins, it can start with a single focus, degenerating to multiple wavelets, and it spreads throughout the entire surface area of both atria. A fibrillatory wave that occurs at a rate of more than 600 beats per minute can cause fatigue in the long run, leading to atrial dilation.

article thumbnail

Atrial Fibrillation Ablation in Congenital Heart Disease: Therapeutic Challenges and Future Perspectives

Journal of the American Heart Association

The increasing prevalence of atrial fibrillation (AF) in adults with congenital heart disease raises significant questions regarding its management. Journal of the American Heart Association, Ahead of Print. Finally, any remaining gaps in knowledge and potential areas of future research are highlighted.

article thumbnail

Atrioventricular Node Ablation for Atrial Fibrillation in a Patient With EVOQUE Tricuspid Valve: A First Reported Case

Journal of Cardiovascular Electrophysiology

ABSTRACT Introduction Atrial fibrillation (AF) is the most common arrhythmia, and atrioventricular (AV) node ablation with pacemaker implantation is a therapeutic option for refractory cases. However, AV node ablation in patients with bioprosthetic tricuspid valves poses technical challenges.

article thumbnail

Use of Direct?Acting Oral Anticoagulants in Patients With Atrial Fibrillation and Significant Tricuspid Regurgitation

Journal of the American Heart Association

BackgroundThere are limited data on the efficacy and safety of direct oral anticoagulants (DOACs) in patients with atrial fibrillation with significant tricuspid regurgitation (TR), which can lead to hepatic dysfunction and intestinal malabsorption.

article thumbnail

Reduction of moderate to severe tricuspid regurgitation after catheter ablation for atrial fibrillation

Heart BMJ

Objective Tricuspid regurgitation (TR) is a progressive disease with high mortality and limited medical treatment options, and its association with atrial fibrillation (AF) has been documented. Results After excluding 36 patients (prior tricuspid valve surgery, intracardiac devices or insufficient data), 70 patients (aged 63.8±9.7